Plain-English translation of NCT05316155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing erdafitinib, a targeted cancer medication, delivered directly into the bladder through a special delivery system. The goal is to treat bladder cancer while keeping side effects lower than if the drug were taken as a pill. The study will enroll about 235 people and take place over several years.
Bladder cancer patients often need frequent monitoring and repeated surgical procedures, and some treatments don't work well for everyone. This trial is exploring whether delivering this medication directly to the bladder—rather than through the whole body—can be more effective and cause fewer side effects for people whose cancer has specific genetic mutations.
You would receive the medication through a special delivery system placed into your bladder, likely during regular office visits. The study has several phases: first, researchers test different doses to find the safest level; then, larger groups of people receive the selected dose. You would have regular follow-up appointments with blood tests, urine tests, and cystoscopy exams (a camera to look inside your bladder). The entire study could last up to about 7 years, though your active treatment phase would likely be shorter.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States